Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

th migraine. An innovative, two-stage, adaptive dose-ranging design formulated through computer simulation was used to facilitate optimal dose selection.

A total of 420 adult patients who experienced migraine attacks, as defined by the International Headache Society criteria, were randomized (330 took drug) to treat a moderate or severe migraine attack with MK-0974 given orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 600 mg, or rizatriptan 10 mg, or placebo. Patients enrolled were primarily female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura.

The first stage of the study evaluated all doses of MK-0974 with rizatriptan and placebo. When a preset number of migraine attacks were treated, an interim efficacy analysis was conducted resulting in dropping the four lowest doses of MK-0974 based on a pre-specified algorithm. The second stage of the study continued with randomization of patients to MK-0974 300 mg, 400 mg or 600 mg or to rizatriptan 10 mg or placebo.

Overall treatment effect was analyzed by comparing the average response of the MK-0974 treatment groups (300 mg, 400 mg and 600 mg) to the response observed in the placebo group. The study was not powered to detect differences between the individual doses of MK-0974 or between MK-0974 doses and rizatriptan.

Study results

For the primary endpoint, the overall treatment effect of MK-0974 in relieving migraine pain (reduction from severe or moderate to mild or none) two hours after dosing was significant compared to placebo (p=0.015). The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent (300 mg; n=38), 48.2 percent (400 mg; n=45) and 67.5 percent (600 mg, n=40); and 69.5 percent for rizatriptan (n=34) compared to 46.3 percent for placebo (n=115).

A similar pattern was observed for secondary measures in which the overall
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
(Date:7/6/2015)... 6, 2015   BioClinica®, Inc ., a ... announced that it has acquired a leading global ... Inc. (Medici).  The acquisition includes affiliates MediciGlobal ... also provides a lost-to-follow-up patient locate service ( ... with Medici, BioClinica will offer pharmaceutical ...
(Date:7/6/2015)... DUBLIN, Ohio , July 6, 2015 ... of The Harvard Drug Group (THDG). A distributor of generic ... and alternate care customers, THDG was owned by Court ... all-cash transaction using existing cash and new debt.  ... , The Harvard Drug Group had revenues of approximately ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
... May 10th, 2007 - Antisense,Pharma, a German biopharmaceutical ... announced, that data from the,Phase IIb-study with AP ... 43rd Annual Meeting of the American Society of,Clinical ... Illinois,U.S.A, from June 1st - 5th. , In ...
... NICE Appraisal Committee concludes that alteplase is clinically,and ... 2007 – A new clinical appraisal,published by the ... the UK has recommended the use of alteplase,for ... based on,its clinical and cost effectiveness compared with ...
Cached Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:7/6/2015)... ... July 06, 2015 , ... Seedstock today announced Pierre Sleiman, founder and ... 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the Small Farmer” – to ... the University of California-San Diego, will explore solutions and methodologies that small farmers and ...
(Date:7/6/2015)... Alameda County, CA (PRWEB) , ... July 06, ... ... Alameda County, CA area, Carlson & Associates has once again teamed up with ... funds helping homeless families to move toward self-sufficiency. FESCO was created especially to ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... In ... can learn how to reduce their risk of having a fracture through the bone ... From Fractures Awareness Day. , “We are participating because our residents need this information ...
(Date:7/6/2015)... ... 2015 , ... The School of Public Health at Georgia ... effort to reduce rates of diabetes and cardiovascular disease in African-American neighborhoods in ... School of Medicine’s Prevention Research Center and the Satcher Health Leadership Institute as ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to ... method to dissolve fat cells and is the first of its kind to be ... commonly known as a double chin. Dr. Green participated in clinical trials for Kybella ...
Breaking Medicine News(10 mins):Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2
... of Hearing Loss Among Diabetics, WASHINGTON, Nov. 10 ... as those without the disease to have hearing loss,according ... Overall,more than 40 percent of people with diabetes in ... with diabetes should ask their doctors to check their ...
... The new Paralda has an advanced HEPA filter lasting ... cleaning efficiency rate of 99.97% - including a UV ... is the only air purifier available in the United ... safe, and Energy Star rated. The 24-hour programmable Paralda ...
... Family Health History Information on National ... Family History Day, Thanksgiving 2008, BETHESDA, Md., ... History Day, as declared by the U.S. Surgeon,General. The American ... family medical history and if they haven,t already,gathered this potentially ...
... Company reports profitability in both operating divisions --, -- Demand ... ... crisis --, BETHESDA, Md., Nov. 10 /Xinhua-PRNewswire/ ... of Western,healthcare products and services in the People,s Republic of China, today,announced ...
... ChromaDex (OTC,Bulletin Board: CDXC), today announced that it ... Minn.) to supply global,analytical reference standards and research ... provides the ability for food and beverage,companies to ... With the introduction of Truvia(TM) rebiana natural sweetener ...
... of promoted products and reduced operating costs continue to,drive ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... in the quarter ended September 30, 2008 totaled,$231.9 million, ... The,primary drivers of the increase in revenue were the ...
Cached Medicine News:Health News:People with Diabetes Urged to Have Their Hearing Checked Regularly 2Health News:For the First Time this Winter Consumers Have an Electronic Green Solution that Eliminates 99.97 Percent of Indoor Air Pollution 2Health News:Know the Myths and Facts About Family Health History: American College of Medical Genetics 2Health News:Know the Myths and Facts About Family Health History: American College of Medical Genetics 3Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 2Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 3Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 4Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 5Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 6Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 7Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 8Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 9Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 10Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 11Health News:Chindex International Inc. Reports Second Quarter FY 2009 Financial Results 12Health News:ChromaDex Partners With Cargill to Provide Global Quality Control Methods and Standards for Sweet Components of Stevia 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance 18
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: